Analyst consensus rating
AbbVie Analyst Rating: Buy
ABBV is rated Buy by 29 analysts with a $276.59 target. As of 2026-08-24.
Direct answer
AbbVie's consensus rating is Buy.
29 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $276.59.
Forecast evidence checked August 24, 2026.
Get free AbbVie email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $264.96
- Average price target
- $276.59
- High price target
- $328.00
- Low price target
- $200.00
- Low target gap
- -24.5%
- Target upside
- +4.4%
- High target gap
- +23.8%
- Target range width
- 48.3%
- Consensus rating
- Buy
- Analysts
- 29
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for AbbVie?
AbbVie has a verified Buy consensus. The same dataset has an average price target of $276.59.
How far are AbbVie's low and high targets from the recorded price?
The low target implies -24.5%, while the high target implies +23.8%.
How many analysts are included in AbbVie's consensus?
The verified consensus includes 29 analysts.
How is AbbVie's target upside or downside calculated?
The average target of $276.59 is divided by the recorded price of $264.96, then one is subtracted to produce +4.4%. This does not guarantee a future return.
When was AbbVie's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.